These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 28281838)

  • 1. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.
    Baldacci F; Lista S; Cavedo E; Bonuccelli U; Hampel H
    Expert Rev Proteomics; 2017 Apr; 14(4):285-299. PubMed ID: 28281838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development.
    Baldacci F; Lista S; Palermo G; Giorgi FS; Vergallo A; Hampel H
    Expert Rev Proteomics; 2019 Jul; 16(7):593-600. PubMed ID: 31195846
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
    Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
    Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
    Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.
    Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL
    Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
    Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
    Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
    Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM
    Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.
    Smith RG; Pishva E; Kouhsar M; Imm J; Dobricic V; Johannsen P; Wittig M; Franke A; Vandenberghe R; Schaeverbeke J; Freund-Levi Y; Frölich L; Scheltens P; Teunissen CE; Frisoni G; Blin O; Richardson JC; Bordet R; Engelborghs S; de Roeck E; Martinez-Lage P; Altuna M; Tainta M; Lleó A; Sala I; Popp J; Peyratout G; Winchester L; Nevado-Holgado A; Verhey F; Tsolaki M; Andreasson U; Blennow K; Zetterberg H; Streffer J; Vos SJB; Lovestone S; Visser PJ; Bertram L; Lunnon K
    Alzheimers Dement; 2024 Oct; 20(10):6722-6739. PubMed ID: 39193893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Cerebrospinal Fluid Levels of Soluble Triggering Receptor Expressed on Myeloid Cells 2 and Chitinase-3-Like Protein 1 in Idiopathic Normal-Pressure Hydrocephalus.
    Yang F; Yang L; Fang X; Deng Y; Mao R; Yan A; Wei W
    J Alzheimers Dis; 2023; 93(4):1341-1354. PubMed ID: 37182875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease.
    Muszyński P; Groblewska M; Kulczyńska-Przybik A; Kułakowska A; Mroczko B
    Curr Neuropharmacol; 2017; 15(6):906-917. PubMed ID: 28183245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.